Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Biogen Pharmachem Industries approved unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported zero revenue from core operations, with total income of Rs. 54.19 lakhs in Q3 FY26 coming entirely from 'other operating income', up sharply from a negative Rs. 10.49 lakhs in Q3 FY25. Profit after tax for Q3 FY26 stood at Rs. 46.23 lakhs versus a loss of Rs. 49.15 lakhs in the year-ago quarter, with EPS of Rs. 0.01. For the nine-month period, the company swung to a profit of Rs. 131.56 lakhs from a loss of Rs. 147.05 lakhs in the corresponding period last year. Paid-up equity capital is Rs. 9,026.03 lakhs while other equity remains negative at Rs. 903.26 lakhs, indicating accumulated losses. The statutory auditors (Goenka Mehta & Associates) issued an unmodified limited review report.
A clear turnaround from losses to profits across both the quarter and nine-month period is positive, but the company has no revenue from core operations, is entirely dependent on other operating income, and carries negative reserves — making the sustainability of profits questionable for retail investors.